Silence Therapeutics (LON:SLN) Issues Quarterly Earnings Results, Beats Estimates By $8.00 EPS

Silence Therapeutics (LON:SLN) issued its quarterly earnings data on Monday. The company reported GBX (13.70) (($0.18)) earnings per share for the quarter, beating the consensus estimate of GBX (21.70) (($0.28)) by GBX 8 ($0.10), Digital Look Earnings reports.

Shares of LON:SLN traded down GBX 5 ($0.07) during trading on Monday, reaching GBX 463 ($6.05). The stock had a trading volume of 64,817 shares, compared to its average volume of 182,641. Silence Therapeutics has a 52 week low of GBX 161 ($2.10) and a 52 week high of GBX 646.50 ($8.45). The firm has a market capitalization of $383.49 million and a price-to-earnings ratio of -17.93. The company has a quick ratio of 3.84, a current ratio of 3.88 and a debt-to-equity ratio of 1.37. The stock has a fifty day simple moving average of GBX 466.62 and a two-hundred day simple moving average of GBX 445.10.

Separately, Peel Hunt reissued a “buy” rating on shares of Silence Therapeutics in a research report on Thursday, July 16th.

About Silence Therapeutics

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Featured Article: Why do earnings reports matter?

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with's FREE daily email newsletter.